MDWD
MediWound Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$11.85
−2.95%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$12.24
From 52W high−39.82%
Volume33443.00
Market cap$152.99M
P/E (TTM)—
P/S (TTM)12.9x
Div yield—
Key dataOct 16, 2026
Open
$12.24
From 52W high
−39.82%
Volume
33443.00
Market cap
$152.99M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.7x
P/E (TTM)
—
RSI (14)
32.6
MomentumView details →
1D Return
−2.95%
YTD Return
−35.21%
SummaryUpdated Jun 1, 2026
MediWound Ltd. (NASDAQ:MDWD) is an Israeli biopharmaceutical company founded in 2000 and headquartered in Yavne, Israel. The company went public on NASDAQ in March 2014. MediWound specializes in developing, manufacturing, and commercializing novel enzymatic bio-therapeutic solutions for tissue repair and regeneration, with a primary focus on wound debridement - the medical process of removing dead, damaged, or infected tissue to promote healing.
Similar companies
Latest newsMore news →
MediWound was awarded an additional $3.3 million by the U.S. Department of War to advance a room-temperature-stable formulation of NexoBrid.24d agoMediWound announced that the independent Data and Safety Monitoring Board completed a pre-specified periodic safety review of the ongoing Phase III VALUE study of EscharEx in patients with venous leg ulcers and recommended the study continue without modification.32d agoMediWound reported a Q2 2026 net loss of $0.77 per share, compared to a loss of $1.23 per share a year ago.64d ago